ID: ALA425912

Max Phase: Preclinical

Molecular Formula: C21H24ClN5O4S2

Molecular Weight: 510.04

Molecule Type: Small molecule

Representations

Canonical SMILES:  C/N=C(\NS(=O)(=O)N1CCS(=O)(=O)CC1)N1CC(c2ccccc2)C(c2ccc(Cl)cc2)=N1

Standard InChI:  InChI=1S/C21H24ClN5O4S2/c1-23-21(25-33(30,31)26-11-13-32(28,29)14-12-26)27-15-19(16-5-3-2-4-6-16)20(24-27)17-7-9-18(22)10-8-17/h2-10,19H,11-15H2,1H3,(H,23,25)

Standard InChI Key:  AQUQEVUSKMXXQD-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 510.04

Molecular Weight (Monoisotopic): 509.0958

AlogP: 1.69

#Rotatable Bonds: 4

Polar Surface Area: 111.51

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.32

CX Basic pKa: 4.52

CX LogP: 1.44

CX LogD: 1.43

Aromatic Rings: 2

Heavy Atoms: 33

QED Weighted: 0.50

Np Likeness Score: -1.09

References

1. Lange JH, van Stuivenberg HH, Veerman W, Wals HC, Stork B, Coolen HK, McCreary AC, Adolfs TJ, Kruse CG..  (2005)  Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity.,  15  (21): [PMID:16140010] [10.1016/j.bmcl.2005.07.054]

2. Wittgen HG, van den Heuvel JJ, van den Broek PH, Dinter-Heidorn H, Koenderink JB, Russel FG..  (2011)  Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4.,  39  (7): [PMID:21511945] [10.1124/dmd.110.037812]

Source

Source(1):

• Scientific Literature